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Abstract
Treatment of Latent Tuberculosis Infection (LTBI) is an important component of any TB control strategy. Acceptance and
completion of treatment is poor. We undertook this study to identify barriers to acceptance & completion of treatment.
Patients attending TB clinics completed a self-administered survey. Medical notes and electronic pharmacy records were
reviewed. 143 surveys were completed. 70 (49%) completed treatment. Patients were less likely to accept treatment (p=
0.01, RR 0.781, CI 0.643-0.950) and less likely to complete treatment (p=0.01, RR 0.640, CI 0.462-0.885) when
concerned about the side effects of LTBI medication. Completion of LTBI treatment is sub-optimal. The major barrier
identified was fear about side effects caused by LTBI medications.  
Introduction
Ireland has one of the lowest TB incidence rates in Western Europe with an average rolling incidence rate of
11/100,000 pop/year 1,2 . Treatment of Latent Tuberculosis Infection (LTBI) is an important component of any TB control
strategy. In recent years, there has been an increase in the number of individuals considered to be at high risk for
LTBI due to travel and migration 3. Increasing rates of conditions such as HIV and treatment with immunosuppresants such
as TNF-blockers have resulted in greater risk of progression from latent to active disease 4. Other at-risk groups
include diabetics, new tuberculin skin test converters, homeless and health care workers (HCWâs). High-risk groups
should receive priority treatment for LTBI 5. However, rates of acceptance and completion of treatment are poor 6-9 . Our
previous study reported that of 243 HCWâs referred to the LTBI clinic, only 158 (65%) attended, 21% accepted and 13%
completed treatment 6. The reasons for non-acceptance and failure to complete treatment in our population, including non
health care workers, have not been elucidated. The objective of this study was to identify the patientsâ views of
LTBI and potential barriers to acceptance and completion of treatment.  
Methods
The Patient Advocacy Committee has responsibility for approving surveys conducted in the hospital and gave approval
for this study. Participation was voluntary. Consent was implied by completion of the questionnaire. Patients were
recruited from two TB outpatient clinics in St James Hospital, Dublin (1) the LTBI clinic which receives referrals
from the occupational health department, GPâs or consultants and (2) the Public health clinic which provides a
contact tracing service. An average 350 new patients are seen between both clinics annually. HIV+ patients with LTBI
are seen in a different clinic, and were not included.
Screening at clinics consists of Mantoux test, chest x-ray, physical examination, medical history and baseline liver
function test. A LTBI diagnosis was made in patients with a positive skin test (based on size listed in the Guidelines
of the Prevention and Control of Tuberculosis in Ireland 2010) in the absence of any clinical or radiological evidence
of active tuberculosis 5. Unless contraindicated, all clinic attendees with LTBI were offered treatment. First line
treatment provided was oral isoniazid 300mg daily for six to nine months. Standardised one to one verbal and written
education regarding diagnosis, treatment, and side effects was provided. Patients were followed up monthly to
six-weekly. Liver function tests were monitored and medications dispensed at clinic. Patients had access to the team
by phone between visits. LTBI consultations, medication and tests are without charge. Patients were recruited between
June 2008 and June 2010 using consecutive sampling. Treatment naive patients, 18 years or older, with a confirmed
diagnosis of LTBI were included. Patients received their diagnosis and education and then were invited to complete the
survey, regardless of their intention to accept or decline treatment. Patients were excluded from the study if they
had a diagnosis of active TB, previous TB treatment or if isoniazid was contraindicated.
The first outcome measure was patient acceptance or refusal of LTBI treatment as recorded in the medical notes. The
second outcome measure was patient views gathered by survey at the first clinic visit. The third outcome measure was
completion of treatment, defined as taking 180 daily doses or more of isoniazid, which was recorded in the electronic
pharmacy dispensing record and medical notes. A survey designed by Shieh et al, was adapted for the Irish healthcare
setting 10. The self administered survey comprises of 7 demographic questions and 21 multiple-choice questions relating
to health beliefs, lifestyle, clinics and treatment regimens. The questionnaire was in English. Professional
interpreters used in clinic could assist the patient in completion where required. All collected data were stored in
Excel (Microsoft) database. R version 2.10.1 was utilised for analysis. Relative risks for acceptance of treatment and
completion of treatment were calculated for groups agreeing/disagreeing with survey statements. 95% confidence
intervals were constructed and univariate p-values obtained.
Results
Acceptance & Completion of LTBI Treatment
150 patients were approached, 5 refused, 2 surveys were incomplete and 143 surveys were completed. 101 of these
patients (70%) accepted treatment. 70 (49%) patients completed treatment. In 16 cases treatment was stopped by a
physician due to side effects and 12 patients failed to attend clinic after commencing treatment (Table 1).
Barriers to Accepting &Completing Latent Tuberculosis Infection Treatment 1
Respondent Demographics & TB Risk Factors
Mean age 39.8 years (range 21 to 88 years). 64.3% of participants were female. 52% were HCWâs, 43% were born in a TB
endemic country, 24% were recent contacts of active TB cases and 17% were due to commence biological agents (Table 2).
Demographics such as gender (p= 0.725), social class (p= 0.225), country of birth (p=0.328) or ethnicity (p= 0.300)
did not influence the participantsâ decision to accept or decline treatment. However, the patientâs occupation and
risk factors did show a trend towards having a statistically significant influence on accepting or declining
treatment. Hospital workers were less likely to accept treatment (p= 0.067) whereas patients due to commence
biological agents were more likely to accept treatment (p=0.096).
Perceived Barriers
Participants had good general knowledge about LTBI. 85% believed that there was a chance that this could wake up and
make them sick and 90% of participants believed that the LTBI treatment would kill the LTBI in their lungs. Life style
and clinic arrangements such as travelling time and expenses, frequency of appointments, times and duration of visits,
taking time off work or college were not identified as barriers to treatment. Elements of the treatment regimen such
as being unable to take paracetamol or alcohol and the need for venepuncture were not identified as barriers. However,
participants were less likely to accept LTBI treatment (p= 0.01, RR 0.781, CI 0.643-0.950) and less likely to complete
LTBI treatment (p=0.01, RR 0.640, CI 0.462-0.885) when concerned about the side effects of LTBI medication (Table
3).  
Discussion
This paper reports the barriers to accepting and completing LTBI treatment. 70% of those recommended to start
treatment commenced it, a result similar to other health centres 8,11 . But less then 50% of those advised to commence
treatment went on to complete it. HCWâs were less likely to accept treatment, whereas patients due to commence
biological agents were most likely to accept treatment. The main barrier to accepting and completing LTBI treatment
was the fear of side effects. The standard treatment of LTBI is isoniazid therapy for 6 to 9 months. This is fraught
with evidence of poor compliance which is particularly worrying in HCWâs whose risk of reactivation poses a
potential risk of nosocomial exposure to tuberculosis. Many of these HCWâs were recruited from countries with high
TB prevalence.  Screening and treating hospital staff is important.  In 2002, 4% of TB cases in New York were in
HCWâs, an increase from 2.5% in 1994 even though overall TB rates had declined. Of the HCWâs with TB, nearly 60%
had positive Mantoux at the start of employment, but the majority did not receive prophylaxis treatment 12.
HCWâs in our study had the lowest treatment acceptance rate (63%). Many of our HCWâs were young female nurses.
Kwara et al found that pregnant women or those planning to become pregnant were less likely to accept and adhere to
treatment 13. Family planning may have contributed to the lower acceptance rate, although we did not find a
statistically significant association with gender. Furthermore, HCWâs might have the opinion that their positive
mantoux is a result of past BCG vaccination i.e. a âfalse positiveâ and opt out of treatment. 35% of those
vaccinated at an older age can have a BCG related positive mantoux test 14,15 . The use of  Interferon-Gamma Release
Assays (IGRA) in addition to mantoux testing has been recommended in the diagnosis of LTBI because IGRA has a higher
specificity and is unaffected by prior BCG vaccination 16,17 .
HCWâs also had the lowest completion rate (42%).  One explanation offered is that this group may never have intended
initiating treatment but were unwilling to refuse the offer of treatment 11. This may be particularly relevant when
being treated in the hospital they also work in. Of the 12 participants who failed to attend clinic after commencing
LTBI treatment, 7 of these were HCW’s. This may be explained by their unwillingness to refuse treatment, however the
multitude of reasons why patients fail to attend appointments cannot be extrapolated from this study. Patientsâ
perception of the degree of risk of developing TB can influence their decisions 10. Patients commencing
immunosuppressive biological agents were the most likely to accept and complete treatment. Their risk of reactivation
of LTBI is 10 to 20 per cent after commencing biological agents 18. This higher risk may have resulted in their
willingness to take treatment, additionally awareness that treatment with biological agents may be denied, if they
refuse LTBI treatment. Twenty two of the 25 patients in this cohort accepted treatment and 1 failed to attend clinic
after commencing LTBI treatment. Biological agents were withheld in all patients who did not complete treatment.
Frequently it is assumed that health beliefs differ among and are influenced by ethnicity and demographics.
Demographic associations with acceptance and completion of LTBI treatment have varied between studies 10,11,13,19 . Despite
the diverse demographics of the participants in the study, neither, social class nor ethnicity influenced their
decision to accept or decline treatment. The chief finding identified in our study is that patients who were concerned
about treatment side effects were less likely to accept and complete treatment. Preventative measures at the clinic
were in line with American Thoracic Society guidelines.  Despite the incidence rate of isoniazid related hepatitis
being only 1 in 1000, patients still had concerns about side effects outweighing the benefits of treatment 20. Treatment
was stopped due to side effects in 16 patients; these included elevated transaminases, peripheral neuropathy, GI upset
and all reversed on cessation of therapy (Table 1). In each case the physician, in conjunction with the patient, made
a decision to stop isoniazid therapy as the risk of the adverse event outweighed the benefit of continuing to treat
LTBI. Published data demonstrate that 10% to 20% of persons taking isoniazid will have some mild, asymptomatic
elevation of liver enzymes 21. Other factors such as giving up alcohol, venepuncture, knowledge and information about
TB, were not significantly associated with treatment completion. Our findings differ from those reported by Shieh,
where concern about venepuncture was an identified barrier 10. A focus group of HCWâs in the US did identify adverse
events as a barrier to taking LTBI treatment 9. The fear of side effects of medication is a genuine concern. 
The option to take a shorter course may be more attractive for patients. Adherence is better with 4 month rifampicin
course compared to isoniazid 22. Rifapentine plus isoniazid once weekly for 3 months has been shown to be as effective
as 9 months of isoniazid 23. Additionally it had a higher completion rate albeit directly observed therapy was utilised.
The population studied was heterogeneous, this reflects the TB clinic population. It was unrealistic to cohort
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patients as the numbers in each category would be small and have weak statistical results. The patient population was
heavily weighted to HCWâs. Their views may not be representative of all patients. However, they are a substantial
population of LTBI patients for whom treatment is recommended. Completion of LTBI treatment is sub-optimal, even in a
population that includes health care workers and high-risk individuals. The causal reasons for non-acceptance and
non-completion of treatment are multifactorial. However this study found that fear of side effects stopped patients
accepting or completing treatment. We need to support patients from decision making to the end of treatment, with the
availability of IGRA, side effect information and shorter treatment regimens.
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